edison tv
Investment Companies
“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Associated equity: VolitionRx
Edison Investment Research has terminated coverage on VolitionRx (VNRX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.
VolitionRx — 7 videos in collection
VolitionRx (NYSE: VNRX) and Edison recently hosted a webinar, during which the company provided insights into its progress in early cancer detection screening. The presentation included updates from Volition’s Dr Jake Micallef (chief scientific officer), Mr Gael Forterre (chief commercial officer) and Dr Andrew Retter, a leading UK-based haematologist and medical consultant at Volition.
Get access to the very latest content matched to your personal investment style.